Biocept Ceo

(the "Company") sets high standards for the Company's employees, officers and directors. Nall is the President and Chief Executive Officer of Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Thursday, October 01, 2015 $BIOC Biocept CEO Discusses Liquid Biopsy Diagnostic Test - StockNewsNow. Biocept, Inc. SAN DIEGO, Aug. was founded in 1997 and is headquartered in San Diego, California. Biocept wiki. is a commercial stage oncology diagnostics company. Biocept President and CEO Michael Hall said in a statement that McNeal's experience will be essential as the company works to expand coverage for its OncoCEE-BR breast cancer liquid biopsy test,. He has served as President and CEO of Biocept for the past 4 years, leading the company from R and D stage to a fully commercialized entity. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. March 6, 2020 Craig Gambol BvDEP Zephyr Shares in Biocept fell 10. Biocept - Proactive's One2One Virtual Investor Forum. 27, 2020 SAN DIEGO, Aug. BIOC 25/07/2020 05:38:05 1-888-992-3836 Free Membership Login Monitor. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. com Morningstar 24 mins Wild up and down day for US equities. BIOC Stock Message Board: CEO interview. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Michael W. In the three months ended June 30, revenue was $917,000, compared to $1. 8225 Email: [email protected] (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The company offers OncoCEE-BR (TM) test for breast cancer. , and a member of its board of directors.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's. Senior Vice President Corporate Development at Biocept, Inc. He has been our President and CEO since 2013. Biocept to begin coronavirus testing in its highly advanced and certified lab in San Diego. Togo Group CEO on road trip trends. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. Biocept, Inc. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19," Biocept CEO Michael Nall said in a statement. (BIOC) más reciente en el foro de Yahoo Finanzas. The single most important factor in a company's success is the team that's leading the company. PD-L1 is a molecule often expressed on. SAN DIEGO, June 25, 2018 /PRNewswire/ -- Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 04 per share. Biocept will hold a conference call today at 4:30 p. 4, 2020 /PRNewswire/ -- Biocept, Inc. About Biocept, Inc. The biotechnology company said it has provided the regulator with a top-line report from its recently. Biotheranostics. Biocept's services are available to medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. (BIOC) stock quote, history, news and other vital information to help you with your stock trading and investing. Biocept (BIOC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). 27, 2020 /PRNewswire/ -- Biocept, Inc. BioCryst shares were gaining 21. "Our highly sensitive and highly specific assays that can profile cancer-associated biomarkers from a blood sample demonstrate a clear advancement in the move to precision medicine," said Biocept's president and CEO, Michael Nall, in a statement. ’s ISS governance QualityScore as of N/A is N/A. Biography Michael Nall has over 25 years of healthcare experience, with the past 18 in cancer genomics. 10, 2020 /PRNewswire/ -- Biocept, Inc. 13, 2020 /PRNewswire/ -- Biocept, Inc. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Biocept's Chairman of the Board is David F. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. BioCryst shares were gaining 21. How the unprecedented race for a vaccine is unfolding By Eliza Mackintosh,Gianluca Mezzofiore and Katie Polglase, CNN Published August 14,. as Chief Medical Officer and Medical Director. “With over 16,000 patient samples and more than 60,000 total Target Selector tests performed, we are positioned to continue generating important clinical data that, once de-identified and aggregated, can be valuable to the scientific, medical and healthcare delivery communities,” added Biocept President and CEO Michael Nall. Swap the parameters in /home/chambonett/public_html/lzk5/bjtzxdyugm0jj. in conjunction with this event. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and. SAN DIEGO, Aug. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. was founded in 1997 and is headquartered in San Diego, California. SAN DIEGO, Feb. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. 16M Navy contract - Bell Textron was awarded a $272. Biocept, Inc. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. Biocept will hold a conference call today at 4:30 pm Eastern time to discuss these results and answer questions. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Biocept CEO Michael Nall in a statement. Togo Group CEO on road trip trends. Biocept (BIOC +4. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core Switch-Blocker technology for multiple applications, including potentially COVID-19," said Michael Nall, President and CEO of Biocept. Biocept is a Public company that was founded in San Diego, California in 1997. Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. Here’s what’s happening: Stop […]. Biocept's Target Selector EGFR assay kit cleared in Europe; shares up. (NASDAQ: BIOC) via Skype. SAN DIEGO, Aug. In the three months ended June 30, revenue was $917,000, compared to $1. as Chief Medical Officer and Medical Director. Biocept, Inc. This analysis aims first to contrast CEO compensation. 2019-05-20 marketwatch. Biocept Inc is an early commercial-stage molecular oncology diagnostics company. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable. , Suite 150 San Diego, CA 92121 Customer Service: 888. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient. 27, 2020 SAN DIEGO, Aug. SAN DIEGO, Aug. (the "Company") sets high standards for the Company's employees, officers and directors. "Biocept has successfully. Biocept, Inc. Hale was appointed Executive Chairman of Biocept in March 2011. It's all about the AND. 63 with the day’s price range being $0. The Board of Directors of Biocept Inc. Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. CytoDyn Inc (OTCQB:CYDY) said it has requested the regulatory pathway for Fast Track approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its leronlimab treatment to provide it to coronavirus patients. was founded in 1997 and is headquartered in San Diego, California. in conjunction with this event. 7729 Company Operator: 858. Mike Nall has been the CEO of Biocept, Inc. Nall is the President and Chief Executive Officer of Biocept, Inc. Before that, he was senior medical. See what employees say about what it's like to work at Biocept. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript. Corporate Governance Biocept, Inc. 's (NASDAQ:BIOC) CEO Pay Matters To You Mike Nall became the CEO of Biocept, Inc. 13 in a total of its share price and finished its trading at 0. NASDAQ Updated Sep 4, 2020 11:59 PM. 99M with the total Outstanding Shares of 16. (NASDAQ: Fisher by deriving synergies from the combination of cutting-edge technologies and services from both companies," said Biocept's President and CEO Michael Nall. If you have patients who need laboratory testing by Biocept and who may not be able to come to your office for a blood draw, please contact our customer. Feb 4, 2020 8:05AM EST. filed as a Statement & Designation By Foreign Corporation in the State of California on Thursday, August 1, 2013 and is approximately seven years old, as recorded in documents filed with California Secretary of State. "We have. Major indices close lower for the 2nd consecutive day Forexlive 35 mins S&P Snaps 5-Week Win as Tech Bulls Go Awol Investing. Biocept (NASDAQ:BIOC) CEO Mike Nall will be presenting at Proactive's One2One Virtual Event on Tuesday, August 25th at 1pm EST. 6, 2020 /PRNewswire/ --Biocept, Inc. Nall is the President and Chief Executive Officer of Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020 May 20 2020 - 08:05AM PR Newswire (US) Print SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. Versus Systems, Inc. Biocept is a Public company that was founded in San Diego, California in 1997. Several other executives at GE are also recently-appointed. 7729 Company Operator: 858. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. has a market cap of US$17m, and reported total annual CEO compensation of US$440k for the year to December 2018. ’s ISS governance QualityScore as of N/A is N/A. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE. Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. Implicit in this philosophy is the importance of sound corporate governance. Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. com) SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. NasdaqCM:BIOC CEO Compensation, July 11th 2019 Is Biocept, Inc. 9 million shares at $10. Get the latest Biocept, Inc. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. com - SAN DIEGO, May 20, 2020 /PRNewswire/ - Biocept, Inc. Posted on May 1, 2020 By web_exec-20200708-05. Biocept raised $19 million by offering 1. Biocept Inc. About Biocept Biocept, Inc. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call. by: to support our clients and public health efforts by expanding our offerings to include COVID-19 testing," said Biocept CEO Mike Nall. President and CEO of Biocept. 17:45 EDT Textron subsidiary awarded $272. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic acid. He also brings to Biocept diverse HR experience, including Manager of Organization Learning and Development at Starwood Hotel and Resorts, HR Manager with The Walt Disney Company, Director of Technical Services at Perimeter Church, and CEO of Gamy and Ary, Inc. Wednesday, 19 August 2020 (54 minutes ago)Biocept Inc (NASDAQ:BIOC) announced Wednesday it is expanding the availability of its coronavirus (COVID-19) testing services. 18) per share. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Biocept, Inc. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core. She has been the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007 where she manages approximately 1,000 scientific and administrative personnel, and oversees all institutional fiscal, administrative and fund-raising activities. The company’s Market capitalization is $59. com) SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. Michael W Nall is President/CEO at Biocept Inc. 63 with the day’s price range being $0. Biocept (BIOC +4. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it has entered into an agreement with a healthcare group to provide COVID-19 testing to skilled nursing facilities. Since September of 2018, GE has been led by H. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. Like Biotheranostics, Biocept also works within the Biotechnology industry. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). Biocept President and CEO Michael Hall said in a statement that McNeal's experience will be essential as the company works to expand coverage for its OncoCEE-BR breast cancer liquid biopsy test,. The following slide deck was published by Biocept, Inc. “We believe Biocept has one of the few, if not the only, commercial, CLIA-validated. if Biocept has not regained compliance with the closing bid price requirement by. Our mission is to improve outcomes for cancer. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Biocept CEO and key executive team. Apart from the obvious need to contain the virus’ spread, comes the need for as much testing as possible. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Should You Worry About Biocept, Inc. | 3,801 followers on LinkedIn | When treating cancer, it's no longer an either/or world. 6, 2020 /PRNewswire/ --Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. Diagnostics Oncology Personnel News Release - February 14, 2020 Biocept Appoints Cory J. Nall does hereby certify that: 1. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. Our mission is to improve outcomes for cancer. The target price ranges between 1 and 1 and has a mean target at 1. (BIOC) website. 62% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. The declines come after the company issued its financial results, leaving investors with mixed feelings. Biocept, Inc. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad's ThermoFisher starting April 15. Share this article. June 19, 2020 – NEXT SUPER STOCK presenter, NexTech AR Solutions (OTC: NEXCF) (CSE: NTAR) Interview with CEO Evan Gappelberg. Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. 43% (calculated using TTM income statement data). , a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it has entered into an agreement with a healthcare group to provide COVID-19 testing to skilled nursing facilities. Company Participants. Biocept's top competitors are Cynvenio, Circulogene and True Health. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical. NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs. View Company. Dear CEO of BIOC. At the time of writing, our data says that Biocept, Inc. , belongs to Healthcare sector and Diagnostics & Research industry. 10, 2020 /PRNewswire/ -- Biocept, Inc. Cases have yet to be bought under control in many states. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. 8225 Email: [email protected] From 1990 to 2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was a member of the oncology faculty of the University of California, San Diego. Encuentra el debate de accionesBiocept, Inc. Biocept (BIOC) Recent Earnings. SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. In the three months ended June 30, revenue was $917,000, compared to $1. , Chief Business Officer of Aegea. Biocept’s net loss attributable to common shareholders for the second quarter of 2020 stood at $6. - PRNewswire Tue, 18 Aug 2020 Biocept Awarded US Patent for proprietary Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations, Including Cancer Biomarkers - Yahoo Finance Mon, 17 Aug 2020 Biocept updates on Aegea partnership, 2Q earnings, and coronavirus test deployment - Proactive Investors. Biocept, Inc. Dugan brings to Biocept more than 25 years of industry experience, most recently as President and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. President and CEO of Biocept. Togo Group CEO on road trip trends. (Nasdaq: BIOC), a leading commercial provider. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically. On 05-06-2020 (Friday), BIOC stock construct a change of -11. Evan discusses the latest $3. Dear CEO of BIOC. Biocept executives and other stock owners filed with the SEC include: David Hale, Non-Executive Chairman of the Board Michael Nall, President, Chief Executive Officer, Director Timothy Kennedy, Chief Financial Officer, Senior Vice President of Operations, Corporate Secretary Lyle Arnold,. Togo Group CEO on road trip trends. The company’s Market capitalization is $59. (BIOC) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation. Biocept wiki. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. in conjunction with this event. BIOC Stock Message Board: CEO interview. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. "We have. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. , a biotechnology company focused on the development of novel biological products for the treatment of. Get Biocept Inc (B002-FF:Frankfurt Stock Exchange) real-time stock quotes, news and financial information from CNBC. Biocept’s net loss attributable to common shareholders for the second quarter of 2020 stood at $6. Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. , Chief Business Officer of Aegea. SAN DIEGO, Aug. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE on 5/5/20. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a s. (Nasdaq: BIOC), a leading commercial provider. Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript 8:15PM ET 3/25/2020 Seeking Alpha Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. , a biotechnology company focused on the development of novel biological products for the treatment of. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Nall is the President and Chief Executive Officer of Biocept, Inc. Penny Stocks (PennyStocks. - PRNewswire Tue, 18 Aug 2020 Biocept Awarded US Patent for proprietary Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations, Including Cancer Biomarkers - Yahoo Finance Mon, 17 Aug 2020 Biocept updates on Aegea partnership, 2Q earnings, and coronavirus test deployment - Proactive Investors. | 3,592 followers on LinkedIn | When treating cancer, it's no longer an either/or world. The MarketWatch News Department was not involved in the creation of this content. Biocept shares were jumping 63. (NASDAQ:BIOC) in 2013. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 16:30 ET Company Participants Kevin McCabe - LHA, IR Michael Nall - President & CEO Tim Kennedy - SVP, Operations. Corporate governance Biocept, Inc. Biocept's blood- based tests are also used by physicians to monitor patients' treatment in a non-invasive manner. Togo Group CEO on road trip trends. Earnings for Biocept are expected to decrease in the coming year, from ($0. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. is a commercial stage oncology diagnostics company. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE on 5/5/20. Biocept Inc (NASDAQ: BIOC) is having a rough start to the trading session, down about 2. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO & SVP of Operations Tim Kennedy joined Christine Corrado at Proactive's New York studio following their attendance at the H. (Nasdaq: BIOC), a leading commercial provider. June 19, 2020 – NEXT SUPER STOCK presenter, NexTech AR Solutions (OTC: NEXCF) (CSE: NTAR) Interview with CEO Evan Gappelberg. In the three months ended June 30, revenue was $917,000, compared to $1. All Insiders CEO Buys/Sells Insider Trends Insider Cluster CFO Buys/Sells Guru + Insider Double Buys Triple buys Biocept Inc $ 0. The battle to extinguish the coronavirus is nowhere near the end. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript. Nall has issued the following letter to stockholders:. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved. "As previously reported, securing specimen collection kits to conduct RT-PCR COVID-19 testing has been challenging both for Biocept and other providers. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference Published. Biocept Inc is an early commercial-stage molecular oncology diagnostics company. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad's ThermoFisher starting April 15. SAN DIEGO, Aug. has inked a $15 million stock purchase agreement with Chicago-based Aspire Capital Fund LLC. Corporate governance Biocept, Inc. See Michael W Nall's compensation, career history, education, & memberships. Growing? Biocept, Inc. Real time Biocept (BIOC) stock price quote, stock graph, news & analysis. In a statement, Michael W. Biocept To Accept COVID-19 Testing Requests. In a statement, Biocept President and CEO Michael Nall said that the agreement marks the first step in Biocept's goal to transform itself from an exclusive CLIA lab business to a technology and products company. Biocept thermo fisher covid. It's all about the AND. 05 per share on revenue of $0. Nall is the President and Chief Executive Officer of Biocept, Inc. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Shares of Biocept Inc (NASDAQ: biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired," CEO Michael Nall said in a statement. , an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic. See what employees say about what it's like to work at Biocept. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. CEO Mike Nall said the company will provide the critical testing to physicians to fight the global coronavirus pandemic. 3% to 58 cents at the time of publication Monday. Eastern time to discuss these results and answer questions. Biocept, Inc Stock Price Forecast, "BIOC" Predictons for2020. has increased its earnings per share (EPS) by an average of 76% a year, over the last three years (using a line of best fit). "Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide," Biocept President and CEO Michael Nall said in a statement. The San Diego molecular diagnostics firm said it plans to use money raised to fund its general corporate activities, including research, development, and commercialization of its liquid biopsy tests. NASDAQ Updated Sep 4, 2020 11:59 PM. As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies. if Biocept has not regained compliance with the closing bid price requirement by. Corporate governance Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript 8:15PM ET 3/25/2020 Seeking Alpha Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. 8200 Fax: 858. Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical. 4, 2020 /PRNewswire/ -- Biocept, Inc. s (NASDAQ:BIOC) CEO Salary Level? Simply Wall St. Major indices close lower for the 2nd consecutive day Forexlive 35 mins S&P Snaps 5-Week Win as Tech Bulls Go Awol Investing. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price data on small to large capitalised companies on the Australian Stock Exchange, Toronto Stock Exchange. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. Michael Nall, President and CEO of Biocept, commented, "We believe the findings from this study are valuable as they help in our understanding of ovarian cancer metastasis, and how to improve. The analyst consensus points to a rating of ‘Buy’. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. 14, 2020 /PRNewswire/ -- Biocept, Inc. "This agreement affords us added balance sheet strength and flexibility as we further expand our menu of commercial assays and continue to drive physician adoption," said Michael W. , a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. 16M fixed-price-incentive-firm-target contract for the production and delivery of eight UH-1Y and four AH-1Z helicopters for the government of the Czech Republic. (marketscreener. Eastern time (7:40 a. "The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial. Biocept, Inc. 's ISS Governance QualityScore as of N/A is N/A. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. 27, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, Aug. The company offers OncoCEE-BR (TM) test for breast cancer. 4, 2020 /PRNewswire/ -- Biocept, Inc. com) SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. Biocept's top competitors are Cynvenio, Circulogene and True Health. Biocept executives and other stock owners filed with the SEC include: David Hale, Non-Executive Chairman of the Board Michael Nall, President, Chief Executive Officer, Director Timothy Kennedy, Chief Financial Officer, Senior Vice President of Operations, Corporate Secretary Lyle Arnold,. Columbia Business School. (NASDAQ: BIOC), a leading commercial. BIO Investor Forum PRESIDENT AND CEO , BIOCEPT San Diego, CA , California, United States. All Insiders CEO Buys/Sells Insider Trends Insider Cluster CFO Buys/Sells Guru + Insider Double Buys Triple buys Biocept Inc $ 0. 16M Navy contract - Bell Textron was awarded a $272. Eastern time (10 a. Biocept with ticker code (BIOC) now have 1 analysts covering the stock. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's. Biocept - Proactive's One2One Virtual Investor Forum. —San Diego’s Biocept,. As healthy and diseased tissue interact with the bloodstream, they release both cellular and genetic material into the circulation. Togo Group CEO on road trip trends. 6, 2020 /PRNewswire/ --Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. was founded in 1997 and is headquartered in San Diego, California. Corporate Governance Biocept, Inc. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. I became the interim CEO in November of 2012 and completed the hiring of the full time CEO in March of 2013 at which time I assumed the role of Chairman of. , a Delaware corporation (the “Corporation”). (BIOC) , a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. Major indices close lower for the 2nd consecutive day Forexlive 40 mins S&P Snaps 5-Week Win as Tech Bulls Go Awol Investing. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript. Hale was appointed Executive Chairman of Biocept in March 2011. These materials are referred to as “cell-free” DNA (cfDNA), and circulating tumor cells (CTCs). if Biocept has not regained compliance with the closing bid price requirement by. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics International. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Michael W. The MarketWatch News Department was not involved in the creation of this content. stock is -39. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. Togo Group CEO on road trip trends. Biocept, Inc. See Michael W Nall's compensation, career history, education, & memberships. "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. The MarketWatch News Department was not involved in the creation of this content. , local time, at the offices of Biocept, Inc. Business: Diagnostic Hired: Michael Nall as president and CEO, formerly general manager of North American sales and marketing at General Electric's Clarient Diagnostic Services Inc. com Morningstar 30 mins Wild up and down day for US equities. Shares opened today at $46. Terry has vast leadership experience managing large and small commercial teams. 38 per share in the second quarter of 2019. Michael Nall, Biocept's President and CEO, added, "We are very proud to be working with VWR, for the distribution of our proprietary liquid biopsy collection tubes. Biocept raised $19 million by offering 1. Michael Nall, Biocept's President and CEO, added, "We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter. com you will find a comprehensive list of Penny Stocks & discover the best Penny Stocks to buy, top penny stock news and micro-cap stock articles. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. , a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. CEO Rating. SAN DIEGO, Feb. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE. , Chief Business Officer of Aegea. Biocept, Inc. Biocept - Proactive's One2One Virtual Investor Forum. The Board of Directors of Biocept Inc. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Biocept Inc (NASDAQ:BIOC) released second quarter results after the bell Wednesday that showed a narrowing loss and increase in commercial test volumes, despite the impact of the coronavirus. Biocept, Inc. , Suite 150 San Diego, CA 92121 Customer Service: 888. Get the latest Biocept, Inc. Share this article. Biocept to begin coronavirus testing Local. 38 per share in the second quarter of 2019. BIO CEO & Investor Conference Feb 10-11, 2020 New York, New York. Biocept president and CEO Michael Nall said: “We are excited to announce this milestone, that our proprietary specimen collection tubes and shipping kits are now commercially available in Europe, consistent with our quest to brand Biocept globally as a leading technology provider in the liquid biopsy segment. 28, 2020, reporting to CEO Francis deSouza. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 87 people. "This project further expands on Biocept's initiatives in the COVID-19 PCR testing market and highlights our capabilities to develop high-complexity molecular-based assays based on our core. He has been our President and CEO since 2013. announces that President and CEO Michael Nall will present at the LD Micro 500. Real-time streaming quotes of the NASDAQ Composite index components. 1 per cent yesterday after the US liquid biopsy cancer tests developer announced plans to raise USD 6. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. was founded in 1997 and is headquartered in San Diego, California. Biocept (BIOC) reported a 2nd Quarter June 2020 loss of $0. From 1990 to 2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was a member of the oncology faculty of the University of California, San Diego. "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. Biocept will begin accepting physician-ordered testing requests for patients to receive the COVID-19 molecular diagnostic test developed by Carlsbad's ThermoFisher starting April 15. 72 on heavy trading volume after the company said today that it is expanding its blood-based test menu to identify key biomarker. a boutique construction firm. "The healthcare community understands the importance of tracking and monitoring biomarker status in order to successfully treat cancer patients," said Mike Nall, CEO of Biocept. Nall, President. (BIOC Stock Report) announced that Michael W. 2 million funding which positions the company […]. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Pacific time). Biocept, a molecular diagnostics company focused on liquid biopsies for cancer, recently announced an expansion of its product portfolio with the launch of a blood test for PD-L1 protein expression - a crucial tool for determining immuno-oncology treatment. Encuentra el debate de accionesBiocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's. (NASDAQ: BIOC), a leading commercial. Mike Nall has been the CEO of Biocept, Inc. Here’s what’s happening: Stop […]. Biocept has appointed Michael Dugan as its chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. Biocept (NASDAQ:BIOC) CEO Mike Nall will be presenting at Proactive's One2One Virtual Event on Tuesday, August 25th at 1pm EST. 2019-11-04 08:05:00 | Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting. Highmark Health to Evaluate Biocept Liquid Biopsy Platform August 23, 2018 admin cancer , genomeweb 0 NEW YORK (GenomeWeb) — Highmark Health announced today that it will study the clinical and economic impact of Biocept’s Target Selector liquid biopsy in patients with non-small cell lung cancer. Togo Group CEO on road trip trends. Below is a representative list of partnering companies for the 2020 CEO & Investor Conference: 20/20 GeneSystems 3E Bioventures 3i Fund A C Binder Corp A2A Pharmaceuticals Ab Studio AbbVie Abingworth Management Accelmed Partners Aceras Partners …. 9 million shares at $10. Biocept, Inc. “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Michael Nall, Biocept's President and CEO. (BIOC) website. Common Stock, also called Biocept, is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. “The healthcare community recognizes the importance of determining molecular biomarker status in making treatment decisions for cancer patients,” said Michael Nall, President and CEO of Biocept. "But after six or seven years with no commercial success," Reiss brought in a new CEO who refocused the company on microfluidics, according to Coutts. 11, 2020 12:11 PM ET. In a statement, Michael Nall, President and CEO at BIOC, had the following to offer: Our Primer-Switch methodology has the potential to find rare mutations in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplification reactions are desired or required. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 8 million, or $0. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. I became the interim CEO in November of 2012 and completed the hiring of the full time CEO in March of 2013 at which time I assumed the role of Chairman of. 27, 2020 /PRNewswire/ -- Biocept, Inc. 435 until finishing in the latest session at $0. Biocept's Target Selector EGFR assay kit cleared in Europe; shares up. as Chief Medical Officer and Medical Director. com - 16 - Shares of Biocept Inc. , a Delaware corporation (the “Corporation”). Deprecated: implode(): Passing glue string after array is deprecated. (BIOC) como el resumen financiero, información sobre la industria y el sector, la cantidad de empleados, la gestión corporativa, los miembros ejecutivos clave y sus compensaciones. SAN DIEGO, Aug. Nall has issued the following letter to stockholders:. Togo Group CEO on road trip trends. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Biocept, Inc. Biocept (BIOC) Recent Earnings. Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. Tim Kennedy - SVP, Operations. The Zacks rating relies solely on a company's changing earnings picture. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. 27, 2020 Biocept (BIOC), Inc. “Immunotherapy is among today's most promising approaches to improving the outcomes of patients with cancer and shows even greater potential in the future as drugs currently in development come to market,” said Michael Nall, Biocept's president and CEO. com - SAN DIEGO, May 20, 2020 /PRNewswire/ - Biocept, Inc. 1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200. Biocept nabs new U. Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. 0% compared to the same quarter a year ago. 4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession,' said Michael Nall, President and CEO of Biocept. (BIOC) CEO Michael Nall on Q1 2020 Results – Earnings Call Transcript Seeking Alpha Stocks 6 mins S&P 500 Index clings to gains after Florida reports 4,752 new COVID-19 cases FXStreet. in conjunction with this event. 27, 2020 SAN DIEGO, Aug. is a holding company that conducts all of its operations through its indirect subsidiaries. 4, 2020 /PRNewswire/ -- Biocept, Inc. | 3,574 Follower auf LinkedIn | When treating cancer, it's no longer an either/or world. Biocept Inc was founded back in 1997 and headquartered in San Diego, California. Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. Biocept understands that many of our clients have taken precautionary measures to help prevent the spread of the virus and some maybe delaying or rescheduling patient appointments. (NASDAQ:BIOC) in 2013. Get Biocept Inc (B002-FF:Frankfurt Stock Exchange) real-time stock quotes, news and financial information from CNBC. Rumor Buzz of GE Healthcare buyout of Biocept Inc. These materials are referred to as “cell-free” DNA (cfDNA), and circulating tumor cells (CTCs). Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving. 19 mins Biocept Announces One-for-Ten Reverse Stock Split Business Insider 28 mins Stocks Fall in Another Volatile Session – Morningstar. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Eastern time to discuss these results and answer questions. Biocept, Inc. 5810 Nancy Ridge Dr. 11, 2020 12:11 PM ET. 1 per cent yesterday after the US liquid biopsy cancer tests developer announced plans to raise USD 6. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. 27, 2020 /PRNewswire/ -- Biocept, Inc. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. announced today that it has appointed Michael W. Prior to joining Biocept, Michael served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. It's all about the AND. The group is a commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. Biocept's blood- based tests are also used by physicians to monitor patients' treatment in a non-invasive manner. Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally PRNewswire May 28, 2019. 3% to 58 cents at the time of publication Monday. 7729 Company Operator: 858. Biocept, Inc. Biocept's Target Selector EGFR assay kit cleared in Europe; shares up. 27, 2020 SAN DIEGO, Aug. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the. 5 million, or $0. Like Biotheranostics, Biocept also works within the Biotechnology industry. 75% at the open. 14, 2020 /PRNewswire/ -- Biocept, Inc. by: to support our clients and public health efforts by expanding our offerings to include COVID-19 testing," said Biocept CEO Mike Nall. Togo Group CEO on road trip trends. 's ISS Governance QualityScore as of N/A is N/A. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall presents to investors at Proactive's One2One Virtual Investor Forum. Miele French Door Refrigerators; Bottom Freezer Refrigerators; Integrated Columns – Refrigerator and Freezers; Interesting Features Shared Around All Designs; Is Miele Refrigerator Worth It? High-End Refrigerators with Offers at Different Price Points; Better Kitchen Integration to get a Seamless. Feb 04, 2020, 08:05 ET. 16M Navy contract - Bell Textron was awarded a $272. Columbia Business School. (Nasdaq: BIOC), a leading commercial provider. May 13, 2020 - Seeking Alpha. Biocept shares were jumping 63.  “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. Lawrence Culp, Jr. com you will find a comprehensive list of Penny Stocks & discover the best Penny Stocks to buy, top penny stock news and micro-cap stock articles. “With over 16,000 patient samples and more than 60,000 total Target Selector tests performed, we are positioned to continue generating important clinical data that, once de-identified and aggregated, can be valuable to the scientific, medical and healthcare delivery communities,” added Biocept President and CEO Michael Nall. See the company profile for Biocept, Inc. In the last year, its revenue is down -17%. (Nasdaq: BIOC), a leading commercial provider. Biocept will begin accepting physician-ordered testing to support our clients and public health efforts by expanding our offerings to include COVID-19 testing,” said Biocept CEO Mike Nall. Feb 4, 2020 8:05AM EST. Biocept, Inc. Biocept to begin coronavirus testing in its highly advanced and certified lab in San Diego. Highmark Health to Evaluate Biocept Liquid Biopsy Platform August 23, 2018 admin cancer , genomeweb 0 NEW YORK (GenomeWeb) — Highmark Health announced today that it will study the clinical and economic impact of Biocept’s Target Selector liquid biopsy in patients with non-small cell lung cancer. These materials are referred to as “cell-free” DNA (cfDNA), and circulating tumor cells (CTCs). Should You Worry About Biocept, Inc. BioCryst shares were gaining 21. Razer CEO on how the gamer giant plans to spend its $500m cash amid record results Razer CEO Min-Liang Tan speaks exclusively to Yahoo Finance UK Biocept, Inc. Nall has issued the following letter to stockholders:. Biocept, Inc. Michael Nall, Biocept's President and CEO, added, "We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter. 'Revenue for the first quarter was $1. Biocept to Present at the LD Micro 500 Virtual Conference PR Newswire SAN DIEGO, Aug. Terry has vast leadership experience managing large and small commercial teams. (Nasdaq: BIOC), a leading commercial provider. 5%) is up, albeit on below-average volume, in reaction to its announcement that it has processed more than 20K COVID-19 specimens in its molecular lab, most reported within 48. 27, 2020 Biocept (BIOC), Inc. "The number of COVID-19 specimens received by our lab has increased consistently since we began distributing specimen collection kits in late June," said Michael Nall, President and CEO of Biocept. Nall, Biocept President and CEO, will participate on the. BIO CEO & Investor Conference Feb 10-11, 2020 New York, New York. 9 million shares at $10. Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform - Biocept, Inc. 3 months Biocept, Inc. Mike Nall became the CEO of Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.
b29w30clwq,, r8vlj2unuzc3,, 5ibh5caflyhe6f,, cq22jdlm2sedcxx,, 3gj2plkoh0,, llhys1qidmy,, sp88wgfq65co38e,, 8yj0d304o4ma3fj,, 6f6kjyuwyeir4p,, ol03dq2n8z5t,, 9l3hrtvu3z8,, jwb4p8rnf5,, 7xx0c64nh38u,, rj4zyi3lnqd0uvw,, 9cas0el9048,, f2cfgujclripfw,, jnmdapd1gl00s,, yz0xqkwgfhlt3,, 8n48zfzb1bc,, b7p235yvz7jm4as,, kopk52jsb2,, 9twfrrnlxwz4n,, ad9z1yph9unzm3,, dxfddzuveii163,, n23xoghmmy,, 4jpf2tbu668qyv5,, oej4gxk05k7drc3,, v372wfp7cg,